Market Tracker

09/28 4:23am ET

Clovis Oncology Inc (NASDAQ:CLVS)

37.44
Delayed Data
As of Sep 27
 +0.62 / +1.68%
Today’s Change
11.57
Today|||52-Week Range
109.18
+6.97%
Year-to-Date
Moving Average Crossover Alert: Clovis Oncology (CLVS)
Sep 26 / Zacks.com - Paid Partner Content
Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades
Sep 21 / TheStreet.com - Paid Partner Content
3 Biotechs That Could Be M&A Targets
Sep 24 / MotleyFool.com - Paid Partner Content
Analysts' Actions -- Clovis, Altria, Sketchers, Wells Fargo and More
Sep 21 / TheStreet.com - Paid Partner Content
Takeover Chatter Around Clovis May Be Overdone
Sep 23 / TheStreet.com - Paid Partner Content
Morning Movers: MYL, XOM, MSFT, GIS, CLVS
Sep 21 / TheStreet.com - Paid Partner Content
'Mad Money' Lightning Round: Broadcom Is Going to $200
Sep 22 / TheStreet.com - Paid Partner Content
Can The Uptrend Continue for Clovis Oncology (CLVS)?
Sep 15 / Zacks.com - Paid Partner Content
Clovis Oncology Charts Suggest Aggressive Buying
Sep 21 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close36.82
Today’s open36.80
Day’s range36.50 - 38.14
Volume2,241,657
Average volume (3 months)2,186,191
Market cap$1.4B
Dividend yield--
Data as of 09/27/2016

Growth & Valuation

Earnings growth (last year)-107.42%
Earnings growth (this year)+4.84%
Earnings growth (next 5 years)--
Revenue growth (last year)-100.00%
P/E ratioNM
Price/Sales--
Price/Book4.70

Competitors

 Today’s
change
Today’s
% change
AXONAxovant Sciences Ltd-0.12-0.82%
HCMHutchison China Medi...-0.11-0.90%
CBMCambrex Corp-0.60-1.30%
DEPODepomed Inc+0.20+0.83%
Data as of 09/27/2016

Financials

Next reporting dateNovember 3, 2016
EPS forecast (this quarter)-$2.01
Annual revenue (last year)$0.00
Annual profit (last year)-$352.9M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Patrick J. Mahaffy
VP, Chief Financial &
Accounting Officer
Daniel W. Muehl
Corporate headquarters
Boulder, Colorado

Forecasts